



for **immunotherapies & innovations  
infectious Diseases**

7<sup>th</sup> Congress – 22 & 23 November 2023 - Lyon, France



**LYONBIOPOLE**  
AUVERGNE-RHONE-ALPES

# Post-Event Report

# OUR STORY

The emergence of new infectious diseases, the re-emergence of “old” infectious diseases, the rise of antibacterial resistance and the difficulty to come out with a new pipeline of new antimicrobial compounds leads to consider the potential of non-conventional approaches, such as immunotherapies as new therapies.

Already on the seventh edition, the **I4ID congress** started on 2017 and the aim was to develop an exclusive conference dedicated to immunotherapies and infectious diseases, something that never existed before. In 2019, The thematic was enlarged to include, with the immunotherapies, all the innovations being developed to fight infectious diseases. Last year, regarding the unique sanitary situation we were going through, we had decided it was imperative to include on this edition program the COVID-19 thematic.

**I4ID** is co-organized by **MabDesign**, the association who the aim is to support and federate the french industrial sector of biotherapy ([www.mabdesign.fr](http://www.mabdesign.fr)) and **Lyonbiopôle**, the healthcare cluster of the Auvergne-Rhône-Alpes region (<https://lyonbiopole.com>). These two emblematic health stakeholders have brought together, for two days, experts from around the world to combine approaches and strengths to innovate in the fields of infectious diseases and immunotherapy.

## From 2017

---



**1250+** attendees



**220+**

High-profile  
speakers



**390+**

Different  
organizations present



**980+**

B2B meetings

# FOCUS IN 2023



## immunotherapies & innovations for infectious diseases

7<sup>th</sup> Congress – 22 & 23 November 2023 - Lyon, France

The **I4ID2023** program included 5 tracks with keynote lectures, pitch talks and industrial talks covering the latest developments and highest innovative projects in the field. Furthermore, it was possible to set up, through an online platform, business meetings during both days (partnering).


The topics covered during this congress were:

- Alternative to antibiotics
- Immunotherapies
- Innovative vaccines
- Diagnostic, prognostic and clinical biomarkers
- EU and international initiatives supporting the value chain of countermeasures against infectious diseases from research to access (roundtable)

# WHO ATTENDED IN 2023?

## KEY FIGURES

- ✓ 270+ participants from different countries
- ✓ 110+ different organizations present
- ✓ 260+ BtoB meetings took place
- ✓ 44 High-profile Speakers
- ✓ 24 Sponsors & Exhibitors



# WHO ATTENDED IN 2023?

## COMPANIES WHICH ATTENDED :

ACROBIOSYSTEMS | ADERLY / Invest in Lyon | Adjuvatis | Advanced Instruments | Affilogic | Africa CDC | AIS Biotech | ALPIONER Therapeutics | AltraBio SAS | AM-Biotech Consulting | ANRS | Maladies infectieuses émergentes | ARXUM | AstraZeneca | AUROBAC THERAPEUTICS | AZENTA LIFE SCIENCES | BACFLY CNRS UAR3426 Biocampus | BCV care | BIOASTER | BioKryo | BioMerieux | BioNTech SE | Bio-Techne | BIOTEM Custom antibodies & services | Biothelis | Boehringer-Ingelheim Animal Health | bYoRNA | CAPEVAL PHARMA | CEA-LETI | CeGaT GmbH | Centre International de Recherche en Infectiologie (CIRI) | CEPI | Cézame Connexions | Charles River Laboratories | CHU Limoges | CIRAD/ UMR Astre | CNRS | CRODA | CYBERNANO | Cynbiose | Deeptope | Department of Internal Medicine, Radboud University Medical Center | DREETS Auvergne-Rhône-Alpes | EFPIA/Vaccines Europe | Eligo Bioscience | EPIMOD | Epynext Therapeutics | ERBC | ESSEC Business School | European Health Emergency Preparedness and Response Authority (HERA) | European Molecular Biology Laboratory, Grenoble | Evotec | FABENTECH | Fab'entech | Faculty of medicine of Geneva | Floralis | Francis Crick Institute | Gavi | GeNeuro SA | Greiner Bio-One | GRIPA | GSK Vaccines | Hospices Civils de Lyon / International Center for Infectiology Research (CIRI) | ICTA | Imcheck Therapeutics | Imperial College London | Innovative Health Initiative (IHI) | Institut Mérieux | Institut Pasteur | Integrated DNA Technologies (IDT) | INTERNATIONAL VACCINE INSTITUTE (IVI) | KyooBe Tech GmbH | LA GAZETTE DU LABORATOIRE | Lyon I University | Mabqi | MAYAKARE - EVALUATION & CONSEILS SCIENCES DE LA VIE | Meddenovo Drug Design | Merck Life Science | MICHADVICES | Miltenyi Biotec | MOLSID | New England Biolabs France | Nicoya | OLINK PROTEOMICS | Oncodesign Services | opial | Osivax | PASREL-Imagerie / CEA | PHAXIAM THERAPEUTICS | Pherecydes Pharma | PLANTIBODIES | Promega | PROTEIGENE | Quantoom Biosciences | RD-BIOTECH | Reckonect SAS | Revvity | Sanofi | Seqens | SGPI | SGS Vitrology | SinoBiological | SPIKIMM | Stemlnov | Tebubio | ten23 health AG | Texcell | The London School of Hygiene & Tropical Medicine (LSHTM) | TRANSGENE | Turing Biosystems | Ultrace DP & SpikImm | Université de Strasbourg | University Lyon 1 | Uppsala University | VALNEVA | VDH Consulting | VIBIOSPHEN | VOXCAN | Yubsis |

# AGENDA 2023

## DAY 1

Wednesday, November 22<sup>nd</sup> 2023

9h30 Registration & Welcome coffee

10h00 Welcome Address

10h05 **Opening lectures** - Lima & Mexico room

Chaired by Daniel Larocque, Sanofi

**CEPI's approach to vaccine libraries and rapid response platforms - an integral part to its 100 Days Mission**

**Martina Ochs**

*Project Leader*

CEPI, Norway

**Title to be defined**

**Sofonias Kifle Tessema**

*Program lead for pathogen genomics*

Africa CDC, Ethiopia

**Trained immunity: from pathophysiology to therapeutic target**

**Mihai Netea**

*Head of the division of Experimental Medicine*

Radboud University Medical Center, Netherlands

11h35 **France2030 initiatives** - Lima & Mexico room

**Accelerating innovation in the field of emerging diseases: the "Biocluster Français pour l'Innovation en Infectiologie (BCF2I)" project**

**Bruno Lina**

*Head of Department*

Laboratoire de Virologie, Centre national de référence virus des infections respiratoires & Centre national de référence entérovirus et paréchovirus, France

**Developing innovative therapies to cure hepatitis B virus infections: from basic science to clinical applications**

**Fabien Zoulim**

*Head of the Hepatology Department*

Hospices Civils de Lyon & Head of the Viral Hepatitis Research Laboratory - INSERM Unit 1052 - France

12h15 Lunch - Poster presentation - B2B - Exhibition Hall

14h00 **Track 1: Alternatives to current antibiotics** - Lima & Mexico room

Chaired by Sébastien Coyne, Aurobac Therapeutics and Ana Antunes, MabDesign

**Challenges of phage therapy in 2023: shared insights from key French private and public players**

**Frédéric Laurent**

*Co-principal investigator*

Hospices Civils de Lyon, Centre International de Recherche en Infectiologie Inserm U1111-UMR CNRS 5308,

ISPB Lyon - Université Lyon 1, France

**Cindy Fèvre**

*Scientific director*

Phaxiam, France

**In situ targeted mutagenesis of gut bacteria**

**David Bikard**

*Head of lab*

Pasteur Institute, France

*Founder*

Eligo Bioscience - France

# AGENDA 2023

## Incentivizing Novelty in Antibiotic Development

**Gosia Majewska**

*Health and industrial organization economist*  
ESSEC Business School, France

## ENABLE-2: A European Antibacterial Drug Discovery Platform

**Anders Karlén**

*Project coordinator*  
ENABLE-2  
*Head of the Department of Medicinal Chemistry*  
Uppsala University, Sweden

## PanHunter - an all-in-one omics data analysis platform

**Erik Schliep**

*Product Manager*  
Evotec, France

15h40 Coffee break - B2B - Exhibition Hall - Poster presentation

16h20 **Track 2: Immunotherapies** - Lima room 16h20

Chaired by Geneviève Inchauspé, Transgene

**Transcriptional signatures reveal the immune response underlying progression and pathogenesis in tuberculosis**

**Anne O'Garra**

*Principal Group Leader*  
Francis Crick Institute, UK

**Monoclonal antibodies for prolonged Covid-19 protection in immunocompromised individuals**

**Cécile Artaud**

*Therapeutic Area Medical Lead*  
AstraZeneca, France

**Life saving stem cell therapy for septic shock and ARDS** 17h20

**Julie Hutin**

*CEO*  
Stemlnov, France

**Securing the supply chain for vaccine adjuvants in the future**

**Dennis Christensen**

*Head of Global R&D*  
Croda, Denmark

**Promega: A Partner for Multidisciplinary Infectious Disease Research and Development**

**Aymeric Morlé**

*Custom/OEM specialist*  
Promega

**Accelerating drug discovery using advanced protein and an-tibody development platforms**

**Yu-Chih Lin**

*Technical Specialist*  
Sino Biological, Germany

18h00 Poster presentation - Exhibition Hall - Wine & Cheese

**Workshop** - Mexico room

**Translational in vivo imaging for anti-infectious diseases treatment and diagnosis follow up by PASREL-Imagerie**

**Ali Ait-Ikhlef**

*Business Development Manager*  
PASREL-Imagerie

**Benoît Delache**

*R&D engineer in animal experimentation*  
PASREL-Imagerie

**Julien Lemaitre**

*Clinical veterinarian and Immunologist*  
PASREL-Imagerie

- Mexico room

**Breakthrough Innovation session**

Chaired by Mélanie Denizot, Lyonbiopôle

**System serology approach on COVID-19 patients' sera reveal specific immune pattern in the heterogeneous population: The COVIDAuRA study**

**Carla Saade**

*Phd student*  
Hospices Civils de Lyon and Centre International de Recherche, France

**Fully automated workflow for cytometry data analysis: Evaluating the effects of adjuvant candidates on memory B and T cells in a phase I clinical trial.**

**Julien Nourikyan**

*Business Development and Partnerships Manager*  
Altrabio, France

**Limitations of threshold-based decisions in Disease X vaccine clinical trials**

**Julien Flaig**

*Epidemiological and health economic simulation modeling*  
Epimod, France

# AGENDA 2023

## DAY 2

Thursday, November 23<sup>rd</sup> 2023

9h00 Welcome coffee

9h30 Keynote lectures - Lima & Mexico room  
Chaired by Daniel Larocque, Sanofi

**Opportunities and Challenges of AI for Infectious Disease Vaccines and Therapeutics**

**Saranya Sridhar**

Global Head of Clinical Franchise for the mRNA Center and Head of Translational Medicine  
Sanofi, United Kingdom

10h30 Coffee break - B2B - Exhibition Hall - Poster presentation

11h00 **Track 3: Diagnostic, prognostic and clinical biomarkers** - Lima room

Chaired by Jean François Litişos, bioMérieux

**Biomarkers and AI to develop personalised medicine in sepsis.**

**Anthony Gordon**

Chair in Anaesthesia and Critical Care, NIHR Research Professor & Senior Investigator  
Imperial College London, United Kingdom

**Endocan, a novel biomarker for pneumonia**

**Philippe Lassale**

Founder  
Biothelisis, France

**Advancing anti-viral and vaccine research with Revvity's fluorescent assays**

**Mathis Laffenetre**

LifeScience Product Leader  
Revvity, France

**A unique solution for antigens that cannot be detected with classical ELISA in medical diagnostic applications: example for inclusion in clinical trial on long COVID.**

**Hervé Perron**

Chief Scientific Officer  
GeNeuro SA, Switzerland

12h00 Lunch - Poster presentation - B2B - Exhibition Hall

14h00 **Track 3: Diagnostic, prognostic and clinical biomarkers** - Lima room

Chaired by Cyril Guyard, Bioaster

**Identification by proteomics of infection markers in the skin: application to a direct diagnosis of Lyme borreliosis**

**Nathalie Boulanger**

Medical entomologist & Research group leader  
Université de Strasbourg, France

**Strategic Partnerships to Address Diagnostic Unmet Needs in Low- and Middle-income Countries**

**Philippe Leissner**

Head of R&D Diagnostic Programme  
BIOASTER, France

**Immune profiling of COVID-19 mRNA vaccines in immunocompromised patients**

**Arnaud Didierlaurent**

Professor at the Faculty of Medicine  
University of Geneva, Switzerland

11h00 **Roundtable: EU and international initiatives supporting the value chain of countermeasures against infectious diseases from research to access** - Mexico room

Animated by Nadia Khelef, National Acceleration Strategy Emerging Infectious Diseases and CBRN Threats

**Marta Tufet Bayona**

Head of Policy  
GAVI, Switzerland

**Anh Wartel**

Deputy Director General / Head  
IVI Europe Regional Office (IERO) - Sweden

**Bangin Brim**

Policy Officer Health Threats  
European Commission - European Health Emergency Preparedness and Response Authority (HERA), Belgium

**Tek-Ang Lim**

Scientific officer  
Innovative Health Initiative (IHI) - Belgium

14h00 **Breakthrough Innovation session** - Mexico room

Chaired by Fabienne Venet, Hospices Civils de Lyon and Mélanie Denizot, Lyonbiopôle

**GlycoFlu, a first-in-class synthetic multivalent sialoside compound with antiviral activity to prevent or treat infections by Influenza viruses**

**Aurélie Juhem**

Chief Executive Officer  
AIS biotech, France

**Neutralizing and Enhancing Monoclonal Antibodies in SARS-CoV-2 Convalescent Patients: Lessons from Early Variant Infection and Impact on Shaping Emerging Variants**

**Frédéric Coutant**

Associate Professor in Immunology  
Hospices Civils de Lyon, France

**Inhalable Nanofitin as new therapeutic for direct application in respiratory tract**

**Sébastien Violet**

Scientist  
Afflogic, France

## **New rapid detection of beta-lactamase producing bacteria using fluorogenic probes**

**Didier Filopon**

*R&D projects manager*

Molsid, France

## **Recombinant multimeric spike proteins: A promising vaccine against COVID-19**

**Marianne Figl**

*Study Director*

Voxcan, France

15h00 Coffee break - B2B - Exhibition Hall - Poster presentation

15h30 **Track 4: Innovative vaccines** - Lima & Mexico room

Chaired by Sherif Abouelhadid, London school of Hygiene & Tropical Medicine and Lionel Cupillard, Boehringer Ingelheim Animal Health

### **Evaluation of vaccination strategies against avian influenza in poultry production networks: comparison of the EVACS tool application in several countries**

**Claire Hautefeuille**

*Veterinary & epidemiologist*

CIRAD/ UMR Astre, France

### **Current strategic approaches in the evaluation of vaccines as complementary tools for prevention and control of HPAI**

**Teshome Mebatsion**

*Executive Director, Viral Disease Research*

Boehringer Ingelheim Santé Animale, France

### **Multivalent pneumococcal conjugate vaccines: trade-offs of an arms race**

**Anthony Scott**

*Epidemiologist*

LSHTM, London

KEMRI-Wellcome Trust, Kenya

### **Recent advancements in the glycoconjugate vaccines field**

**Francesco Berti**

*Senior Director*

GSK Vaccines, Italy

### **Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate**

**Florence Nicolas**

*Chief Development Officer and Co-Founder*

Oshivax, France

17h10 Announcement of next year edition

17h20 End of the Congress



# SCIENTIFIC ADVISORY BOARD




**Geneviève Inchauspé**

*Senior Director, R&D Programs*  
Transgene



**Sandra Morel**

*Director, Research Project Leader, Discovery Performance Unit*  
GSK Vaccines



**Bruno Lina**

*University Professor and Hospital Practitioner, Director National Reference Center for respiratory infections virus, VirPath Laboratory, University Lyon 1*



**Cyril Guyard**

*Deputy CSO*  
Bioaster



**Sébastien Coyne**

*Senior Project Leader, Discovery Research*  
Aurobac Therapeutics



**Laure Delhon**

*Events Manager and Communication*  
MabDesign



**Natalia Bomchil**

*Innovation Director*  
Lyonbiopôle



**Daniel Larocque**

*Microbiology-Immunology Platform Manager*  
Sanofi



**Michel Perez**

*Head of Development Of Innovation Department*  
Pasteur Institute



**Jean François Litjós**

*Scientific and medical Expert Open innovation and Partnership*  
bioMérieux

# SCIENTIFIC ADVISORY BOARD



**Fabienne Venet**

*University professor, Hospital practitioner*

Hospices Civils de Lyon



**Frédéric Reynard**

*Global Project Leader*

Boehringer Ingelheim



**Hervé Raoul**

*Directeur adjoint*

ANRS | Maladies infectieuses émergentes



**Robbert van der Most**

*Vice President Translational Science*

BioNTech



**Sherif Abouelhadid**

*Head at Biological and Pharmacological Pillar at Antimicrobial Resistance Centre*

London school of Hygiene & Tropical Medicine



**Nadia Khelef**

*Coordinator*

National Acceleration Strategy  
Emerging Infectious Diseases and  
CBRN Threats, France

*General investment secretary office*

Health Innovation Agency, France

# ORGANISATION COMMITTEE



**Laure Delhon**  
**Events Manager and**  
**Communication**  
**MabDesign**



**Ana Antunes**  
**Head of Scientific Events**  
**and Communication**  
**MabDesign**



**Natalia Bomchil**  
**Innovation Director**  
**Lyonbiopole**



**Sally Peschiera**  
**Events Manager**  
**Lyonbiopole**



**Stéphanie Pelège**  
**Head of**  
**Communication**  
**Lyonbiopole**

# 2023 SPONSORS

## Platinum Sponsor

**sanofi**

## Silver Sponsor



## Bronze Sponsors

**biotechne®**


CRODA



**revvity**

**SB Sino Biological**

# 2023 EXHIBITORS



## Supporting partners



## Institutional and Media partners





# I4ID



**immunotherapies & innovations**  
for **infectious Diseases**

8th Congress 2024

**27-28 November 2024 – LYON, FRANCE**

For more information,  
Please contact Laure Delhon – MabDesign at:  
[laure.delhon@mabdesign.fr](mailto:laure.delhon@mabdesign.fr) or tel. 0033 (0)4 78 02 39 92

## Follow Us



I4IDCongress



I4IDcongress

#I4ID2024